

Ref: Fin-0016/2024

FORM-3

April 24, 2024

The General Manager

Pakistan Stock Exchange Limited
Stock Exchange Building
Stock Exchange Road
Karachi -74000.

SUBJECT: FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2024

Dear Sir

We are pleased to inform you that the Board of Directors of Hoechst Pakistan Limited (formerly Sanofi-Aventis Pakistan Limited) (the Company) in its meeting held on Wednesday, April 24, 2024 at 11:00 a.m. at Head Office of the Company and through video link arrangement has approved the condensed interim financial statements (un-audited) of the Company for the quarter ended March 31, 2024 and recommended the following:

(i) **CASH DIVIDEND:**

Nil

(ii) **BONUS SHARES:**

Nil

(iii) **RIGHT SHARES:**

Nil

(iv) **ANY OTHER ENTITLEMENT / CORPORATE ACTION:**

Nil

(v) **ANY OTHER PRICE-SENSITIVE INFORMATION:**

Please refer below.


The financial results of the Company for the quarter ended March 31, 2024 are enclosed as **Annexure – A** to this letter.

Material Information: Formation of a wholly owned subsidiary to carry out wellness & nutraceutical business

In accordance with Sections 96 and 131 of the Securities Act, 2015, we are enclosing herewith a Form, disclosing that the Board of Directors of Hoechst Pakistan Limited (the Company) has approved formation of a wholly owned local subsidiary, which will be engaged in the business of manufacturing and distributing wellness and nutraceutical products subject to all applicable regulatory approvals (**Annexure – B**).

The Quarterly Report of the Company for the quarter ended March 31, 2024 will be transmitted through PUCARS separately, within the specified time and shall also be made available on Company's website www.hoechst.com.pk.

Yours sincerely



Syed Muhammad Taha Naqvi
Company Secretary

Encl: As above.

Cc:

Director Company Law Division Securities and Exchange Commission of Pakistan NIC Building, Jinnah Avenue Blue Area, Islamabad	Director Enforcement Department Securities and Exchange Commission of Pakistan NIC Building, Jinnah Avenue Blue Area, Islamabad	Director Securities Market Division Securities and Exchange Commission of Pakistan NIC Building, Jinnah Avenue Blue Area, Islamabad	Executive Director / HOD Offsite-II Department Supervision Division Securities and Exchange Commission of Pakistan NIC Building, Jinnah Avenue Blue Area, Islamabad
--	--	---	---

Annexure A

Hoechst Pakistan Limited (formerly Sanofi-Aventis Pakistan Limited)

Condensed Interim Statement of Profit or Loss

For the quarter ended March 31, 2024 (Un-audited)

	March 31, 2024	March 31, 2023
	----- Rupees in '000 -----	
REVENUE - NET	6,287,309	4,762,608
Cost of sales	(4,660,772)	(3,121,359)
GROSS PROFIT	<u>1,626,537</u>	<u>1,641,249</u>
Distribution and marketing costs	(672,686)	(664,633)
Administrative expenses	(259,578)	(181,415)
Other expenses	(62,314)	(992,992)
Other income	59,873	16,951
	<u>(934,705)</u>	<u>(1,822,089)</u>
OPERATING PROFIT / (LOSS)	<u>691,832</u>	<u>(180,840)</u>
Finance costs	(33,114)	(107,645)
PROFIT / (LOSS) BEFORE TAXATION	<u>658,718</u>	<u>(288,485)</u>
Taxation - Current	(275,485)	(99,474)
- Deferred	(47,417)	30,816
	<u>(322,902)</u>	<u>(68,658)</u>
PROFIT / (LOSS) FOR THE PERIOD	<u>335,816</u>	<u>(357,143)</u>
EARNINGS / (LOSS) PER SHARE - basic and diluted (Rupees)	<u>34.82</u>	<u>(37.03)</u>

AMTale



Annexure B

DISCLOSURE FORM
IN TERMS OF SECTIONS 96 AND 131 OF THE SECURITIES ACT, 2015

Name of Company	Hoechst Pakistan Limited (formerly Sanofi-Aventis Pakistan Limited)
Date of Report	April 24, 2024
Name of Company as specified in The Memorandum	Hoechst Pakistan Limited
Company's Registered Office	Plot 23, Sector 22, Korangi Industrial Area, Karachi-74900
Contact Information	Tel: (021) 35060221-35

Disclosure of inside information by listed company:

The Board of Directors of Hoechst Pakistan Limited (the Company) has approved formation of a wholly owned local subsidiary, which will be engaged in the business of manufacturing and distributing wellness and nutraceutical products subject to all applicable regulatory approvals.

The Board of Directors believe that this investment will be beneficial for the shareholders of the Company in the long run.

Pursuant to the requirements of the Securities Act, 2015, the Company has duly caused this form/statement to be signed on its behalf by the undersigned hereunto duly authorized.

For and on behalf of
Hoechst Pakistan Limited
(formerly Sanofi-Aventis Pakistan Limited)



Syed Muhammad Taha Naqvi
Company Secretary

